NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.54
(5.26%)
USD 0.54
(5.26%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 9.03 Million USD | -44.91% |
| 2022 | 16.39 Million USD | -31.61% |
| 2021 | 23.97 Million USD | 57.36% |
| 2020 | 15.23 Million USD | 35.81% |
| 2019 | 11.22 Million USD | 19.86% |
| 2018 | 9.36 Million USD | -7.12% |
| 2017 | 10.07 Million USD | -34.47% |
| 2016 | 15.38 Million USD | 202.95% |
| 2015 | 5.07 Million USD | -32.64% |
| 2014 | 7.53 Million USD | -51.84% |
| 2013 | 15.65 Million USD | -18.64% |
| 2012 | 19.23 Million USD | 20.5% |
| 2011 | 15.96 Million USD | 2.88% |
| 2010 | 15.51 Million USD | -11.45% |
| 2009 | 17.52 Million USD | 25.44% |
| 2008 | 13.96 Million USD | -41.61% |
| 2007 | 23.92 Million USD | 101.6% |
| 2006 | 11.86 Million USD | 233.13% |
| 2005 | 3.56 Million USD | 0.0% |
| 2003 | 1.31 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.92 Million USD | -26.73% |
| 2024 Q1 | 5.35 Million USD | -40.7% |
| 2023 Q1 | 14.82 Million USD | -9.6% |
| 2023 Q3 | 12.85 Million USD | -19.72% |
| 2023 Q2 | 16 Million USD | 7.98% |
| 2023 Q4 | 9.03 Million USD | -29.71% |
| 2023 FY | 9.03 Million USD | -44.91% |
| 2022 Q2 | 21.54 Million USD | -13.11% |
| 2022 Q3 | 22.37 Million USD | 3.86% |
| 2022 FY | 16.39 Million USD | -31.61% |
| 2022 Q4 | 16.39 Million USD | -26.71% |
| 2022 Q1 | 24.79 Million USD | 3.4% |
| 2021 Q4 | 23.97 Million USD | 95.91% |
| 2021 FY | 23.97 Million USD | 57.36% |
| 2021 Q1 | 14.07 Million USD | -7.65% |
| 2021 Q2 | 13.6 Million USD | -3.33% |
| 2021 Q3 | 12.23 Million USD | -10.03% |
| 2020 FY | 15.23 Million USD | 35.81% |
| 2020 Q3 | 17.08 Million USD | 28.71% |
| 2020 Q2 | 13.27 Million USD | 40.07% |
| 2020 Q1 | 9.47 Million USD | -15.55% |
| 2020 Q4 | 15.23 Million USD | -10.79% |
| 2019 FY | 11.22 Million USD | 19.86% |
| 2019 Q1 | 9.72 Million USD | 3.84% |
| 2019 Q2 | 9.87 Million USD | 1.54% |
| 2019 Q3 | 14.6 Million USD | 47.95% |
| 2019 Q4 | 11.22 Million USD | -23.17% |
| 2018 Q3 | 10.36 Million USD | -11.45% |
| 2018 FY | 9.36 Million USD | -7.12% |
| 2018 Q4 | 9.36 Million USD | -9.69% |
| 2018 Q2 | 11.7 Million USD | -15.32% |
| 2018 Q1 | 13.82 Million USD | 37.15% |
| 2017 Q3 | 11.05 Million USD | -8.4% |
| 2017 Q4 | 10.07 Million USD | -8.84% |
| 2017 Q2 | 12.07 Million USD | -4.83% |
| 2017 Q1 | 12.68 Million USD | -17.55% |
| 2017 FY | 10.07 Million USD | -34.47% |
| 2016 Q4 | 15.38 Million USD | 1.59% |
| 2016 Q1 | 4.93 Million USD | -2.88% |
| 2016 Q2 | 7 Million USD | 42.06% |
| 2016 Q3 | 15.14 Million USD | 116.15% |
| 2016 FY | 15.38 Million USD | 202.95% |
| 2015 FY | 5.07 Million USD | -32.64% |
| 2015 Q1 | 8.15 Million USD | 8.2% |
| 2015 Q2 | 10.17 Million USD | 24.76% |
| 2015 Q3 | 6.69 Million USD | -34.24% |
| 2015 Q4 | 5.07 Million USD | -24.11% |
| 2014 Q3 | 11.04 Million USD | -18.28% |
| 2014 Q4 | 7.53 Million USD | -31.75% |
| 2014 Q2 | 13.51 Million USD | -21.37% |
| 2014 Q1 | 17.18 Million USD | 9.81% |
| 2014 FY | 7.53 Million USD | -51.84% |
| 2013 Q2 | 12.82 Million USD | -16.79% |
| 2013 Q1 | 15.41 Million USD | -19.85% |
| 2013 Q4 | 15.65 Million USD | 27.81% |
| 2013 FY | 15.65 Million USD | -18.64% |
| 2013 Q3 | 12.24 Million USD | -4.54% |
| 2012 FY | 19.23 Million USD | 20.5% |
| 2012 Q1 | 14.04 Million USD | -12.03% |
| 2012 Q4 | 19.23 Million USD | 40.71% |
| 2012 Q3 | 13.67 Million USD | 13.22% |
| 2012 Q2 | 12.07 Million USD | -14.02% |
| 2011 Q3 | 18.3 Million USD | 21.71% |
| 2011 Q2 | 15.03 Million USD | 2.52% |
| 2011 FY | 15.96 Million USD | 2.88% |
| 2011 Q1 | 14.66 Million USD | -5.47% |
| 2011 Q4 | 15.96 Million USD | -12.78% |
| 2010 Q1 | 16.16 Million USD | -7.74% |
| 2010 Q2 | 13.67 Million USD | -15.44% |
| 2010 Q3 | 13.11 Million USD | -4.07% |
| 2010 Q4 | 15.51 Million USD | 18.32% |
| 2010 FY | 15.51 Million USD | -11.45% |
| 2009 Q2 | 13.02 Million USD | -12.9% |
| 2009 FY | 17.52 Million USD | 25.44% |
| 2009 Q1 | 14.95 Million USD | 7.08% |
| 2009 Q3 | 15.24 Million USD | 16.98% |
| 2009 Q4 | 17.52 Million USD | 14.97% |
| 2008 FY | 13.96 Million USD | -41.61% |
| 2008 Q1 | 22.27 Million USD | -6.88% |
| 2008 Q2 | 19.12 Million USD | -14.13% |
| 2008 Q3 | 17.42 Million USD | -8.91% |
| 2008 Q4 | 13.96 Million USD | -19.83% |
| 2007 Q3 | 8.15 Million USD | -12.48% |
| 2007 Q1 | 11.48 Million USD | -3.23% |
| 2007 FY | 23.92 Million USD | 101.6% |
| 2007 Q4 | 23.92 Million USD | 193.27% |
| 2007 Q2 | 9.32 Million USD | -18.84% |
| 2006 FY | 11.86 Million USD | 233.13% |
| 2006 Q4 | 11.86 Million USD | 0.0% |
| 2005 FY | 3.56 Million USD | 0.0% |
| 2005 Q4 | 3.56 Million USD | 0.0% |
| 2003 FY | 1.31 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 53.387% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | -57.497% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 91.785% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 88.908% |
| Azitra, Inc. | 5.11 Million USD | -76.601% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | 9.561% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -9272.244% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | 9.831% |
| CEL-SCI Corporation | 30.52 Million USD | 70.408% |
| iBio, Inc. | 28.73 Million USD | 68.56% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 91.057% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | -19.389% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 86.224% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -106.652% |
| NanoViricides, Inc. | 12.82 Million USD | 29.548% |
| Oragenics, Inc. | 4.96 Million USD | -81.905% |
| BiomX Inc. | 58.15 Million USD | 84.466% |
| BiomX Inc. | 58.15 Million USD | 84.466% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 89.301% |
| Palatin Technologies, Inc. | 10.74 Million USD | 15.902% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 82.299% |
| Theriva Biologics, Inc. | 60.21 Million USD | 84.996% |